Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Proteinase K Market Size
The global proteinase K market size was valued at around USD 1.3 billion in 2023 and is estimated to grow at 7.5% CAGR from 2024 to 2032. Factors such as greater technological advancement in biotechnology, the rising prevalence in infectious and chronic diseases are driving the growth in market.
To get key market trends
The rise in chronic diseases is due to growing geriatric population, sedentary lifestyle, and unhealthy eating patterns resulting in heart disease, diabetes, and cancer. The World Health Organization (WHO) states that non-communicable diseases are responsible for over 71% of the deaths globally whereas infectious diseases like tuberculosis and HIV remain significant public health concerns across globe.
Proteinase K Market Report Attributes
Report Attribute
Details
Base Year:
2023
Proteinase K Market size in 2023:
USD 1.3 Billion
Forecast Period:
2024 to 2032
Forecast Period 2023 - 2032 CAGR:
7.5
2023 Value Projection:
USD 2.5 Billion
Historical Data for:
2021 - 2023
No of Pages:
130
Tables, Charts & Figures:
125
Segments Covered:
Form, Therapeutic Area, Application, End Use, & Region
Growth Drivers:
Increasing prevalence of chronic and infectious diseases
Advancements in biotechnology
Technological progress
Government investment in research
Pitfalls Challenges:
High cost of enzymes
What are the growth opportunities in this market?
Further, innovations in stabilizing proteinase K both in the liquid and powder forms are improving its stability, shelf life, and therefore compatibility with more reagents. These changes make the enzyme more appropriate for use in automated processes and high-throughput systems, driving demand from biotech and pharmaceutical companies.
Proteinase K is a class of broad-spectrum serine protease enzyme and common tool in molecular biology, since it is used to digest proteins and eliminate unwanted materials including nucleases. The ability of proteinase to sever polypeptide bonds renders the enzyme vital for any process such as genomic study, DNA in situ hybridization, or isolation of mitochondria that requires efficient protein breakdown for nucleic acid extraction.
Proteinase K Market Trends
The developments in biotechnology are propelling the advances in the market, enhancing its applications across different sectors.
The production of recombinant proteinase K has been facilitated by the advances in recombinant DNA technology which has dramatically increased purity and achieved greater activity. This is particularly useful for sensitive molecular biology work such as genomic DNA extraction and diagnostic testing.
Moreover, proteinase K is increasingly being utilized in new gene-editing technologies such as CRISPR, where it is used for the efficient removal of proteins and other contaminants from nucleic acids to enhance the editing efficiency.
Also, advanced biotechnology and the creation of platforms of nucleic acid amplification testing and sequencing-based testing for diagnostics. These advancements in biotechnology are broadening the scope of proteinase K, driving its adoption across diagnostics, research, and drug development sectors.
Proteinase K Market Analysis
Learn more about the key segments shaping this market
Based on form, the market is segmented into powder and liquid. The powder segment dominated the market in 2023 and accounted for USD 735.7 million.
Powdered proteinase K has a much longer shelf life compared to its liquid version, making it storable in critical conditions. This stability is required for laboratory applications where enzymes are often required to work for extended amounts of time with no refrigeration.
Moreover, laboratories specializing in large scale applications can save on shipping and production costs with these powdered forms, making them an economically viable option. Therefore, powdered proteinase K is a preferred choice for a myriad of pharmaceutical and biotech firms is evidence to its cost advantages.
Based on therapeutic area, the proteinase K market is segmented into infectious diseases, oncology, diabetes, cardiology, and other therapeutic areas. The infectious diseases segment is anticipated to reach USD 795.3 million by 2032.
Due to the increased prevalence of infectious diseases across the globe, there is a greater demand for faster and precise diagnostic testing. Proteinase K is important in molecular diagnostics since it assists in the isolation and purification of nucleic acids from pathogens. This significantly bolsters the demand for diagnostic tools that utilize proteinase K.
Additionally, proteinase K is a major component in DNA and RNA extraction and purification which is ultimately helpful in creating vaccines and therapeutics. This highlights the critical importance of such enzymes in both research and diagnostic processes.
Learn more about the key segments shaping this market
Based on application, the proteinase K market is segmented into isolation and purification of genomic DNA & RNA, in situ hybridization, mitochondria isolation, and other applications. The isolation and purification of genomic DNA & RNA segment dominated the market in 2023 with a share of 40.9%.
In the nucleic acid extraction process, proteinase K is essential for preparing and purifying biological tissues, cells, or even body fluids. It is one of the most preferred enzymes in molecular biology applications like PCR, cloning, and sequencing that need both RNA and DNA of superior quality. As the research expands in genomics and molecular diagnostics, the reliable extraction of nucleic acids is fueling the growth of this segment.
Moreover, the advancements in proteinase K extraction protocols and the emergence of specialized kits that utilize proteinase K for genomic DNA and RNA have increased the throughput and reproducibility of the extractions. Novel techniques in automation of sample processing have also simplified these isolations for laboratories performing large scale extractions. This advancement is tremendously accelerating the growth of this application segment.
Based on end use, the proteinase K market is segmented into biotechnology companies, contract research organizations, diagnostic laboratories, and other end users. The biotech companies segment is anticipated to reach USD 936.1 million by 2032.
Biotech firms are heavily engaged in the processes of research and development for a number of fields such as genomics proteomics and molecular biology.
Proteinase K is important for various applications such as nucleic acid isolation, protein degradation, and sample preparation which are fundamental to biotech research. There is an increase in proteinase K innovation because there is a need for high-quality reagents and enzymes in advanced research and product development.
Also, the booming of the biopharmaceutical industry in the development of biologics and biosimilars has significantly increased the demand for few enzymes including the proteinase K. The biopharmaceutical industry is developing, prompting biotech firms to seek effective tools for research and production processes, thereby contributing to the segment's growth.
Looking for region specific data?
The U.S. dominated the North American market with the largest revenue of USD 456.2 million in 2023.
The U.S. hosts numerous academic and research institutions that works on genetic and cellular research, which accounts for the high demand of proteinase K. This suggests that the expansion of federal funding in science increases the need for molecular biology tools or biological appliances, such as enzymes.
Moreover, the challenges posed by infectious diseases, such as COVID-19, have further made it obligatory to test and conduct research that requires proteinase K, which increases the demand for enzymes used in nucleic acid extraction. Such benefits associated with proteinase K will spur the country level market growth.
Asia Pacific proteinase K market is anticipated to witness lucrative growth between 2024 and 2032.
The Asia Pacific region comprises well-developed biopharmaceutical industry, which depends on molecular biology practices such as the preparation of proteinase K for nucleic acid extraction and purification. The advancements in biopharmaceuticals are driving research in genetic therapies and diagnostics, thus increasing the need for proteinase K.
Additionally, in this region investment in genomics and personalized medicine research is also high. The increase in funding in genomic studies is increasing the demand for quality reagents like proteinase K. This trend is beneficial for the overall market expansion for products that contain enzymes that aid in genetic engineering.
UK is anticipated to witness robust growth in the global proteinase K market.
The UK has seen advancement in its health and biotechnology industries. A lot of biotech companies are involved in genomic studies and ever increasing in their workflows’ needs for enzymes such as proteinase K.
Also, the government of the UK has actively participated in the funding of health and biotechnology research. The country’s funding schemes focused on the improvement of health research may have an increase in the demand for molecular biology tools such as proteinase K.
Japan is anticipated to witness high growth in proteinase K market, during the forecast period.
Japan has a strong position with regard to genomic research in precision medicine and personalized therapies. This emphasis leads to the need for enzymes that assist in genetic research, proteinase K.
Additionally, Japan has highly favorable regulatory framework for biotechnology and pharmaceutical, thus boosting R&D investment opportunities. The Pharmaceuticals and Medical Devices Agency (PMDA) provides a streamlined approval process for new biotech products, thus there is demand for more research tools such as proteinase K, thereby augmenting the country level market growth.
Proteinase K Market Share
The competition in the market is characterized by fierce competition due to the increasing needs for Proteinase K. In addition to the well-known players, novel formulations that seek a competitive edge are also forthcoming, especially in North America where technology is prioritized. Innovations in Proteinase K are among the main differentiators in the market that compel companies to collaborate with other manufacturers or even research institutions to produce reputable high quality, high efficiency Proteinase K solutions. Therefore, competitive edge is determined by the rapid achievement of innovation and progress in this market.
Proteinase K Market Companies
Prominent players operating in the proteinase K industry include:
Abcam
Agilent Technologies
Bioline (Meridian Biosciences)
BIORON
F. Hoffmann-La Roche
Merck
Minerva Biolabs
MP BIOMEDICALS
New England Biolabs
Norgen Biotek
Promega Corporation
QIAGEN
Sisco Research Laboratories
Takara Bio
Thermo Fisher Scientific
USPs for the top players:
Expansion of production facilities to meet growing demand in pharmaceutical and biotechnology sectors.
Strategic partnerships with research institutions for new product development and applications.
Establishment of regional distribution networks to improve product accessibility.
Proteinase K Industry News:
In May 2023, QIAGEN expanded its enzyme offerings to support individual life science research labs globally. This initiative allowed researchers to customize their assays and workflows by providing high-quality enzymes as individual products. This strategy increased the company’s competitiveness in the market.
In February 2022, Merck, Germany, successfully completed its acquisition of Exelead. Following this acquisition, Merck planned to invest in this company to scale up its technology. This strategy enhanced the company’s reputation in the market.
The proteinase K market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:
to Buy Section of this Report
Market, By Form
Powder
Liquid
Market, By Therapeutic Area
Infectious diseases
Oncology
Diabetes
Cardiology
Other therapeutic areas
Market, By Application
Isolation and purification of genomic DNA & RNA
In situ hybridization
Mitochondria isolation
Other applications
Market, By End Use
Biotechnology companies
Contract research organizations
Diagnostic laboratories
Other end users
The above information is provided for the following regions and countries:
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Netherlands
Asia Pacific
China
Japan
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
Author: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
How much is the North American proteinase K industry worth?+
U.S. led the North American proteinase K market with revenues of USD 456.2 million in 2023, supported by numerous academic and research institutions engaged in genetic and cellular research and increased federal funding for scientific research.
Who are some of the prominent players in the proteinase K industry?+
Key players in the proteinase K industry include Abcam, Agilent Technologies, Bioline (Meridian Biosciences), BIORON, F. Hoffmann-La Roche, Merck, Minerva Biolabs, MP BIOMEDICALS, New England Biolabs, and Norgen Biotek.
Why is the powdered proteinase K segment dominating the market?+
The powdered proteinase K segment dominated the market in 2023, accounting for USD 735.7 million, due to its greater stability, longer shelf life, and easier storage conditions compared to its liquid counterpart.
How big is the proteinase K market?+
The global proteinase K industry was valued at approximately USD 1.3 billion in 2023 and is estimated to grow at a 7.5% CAGR from 2024 to 2032, driven by the increasing prevalence of chronic and infectious diseases and advancements in biotechnology.